José Miguel Rivera-Caravaca

Profesor Permanente Laboral

Universidad de Murcia

Spain

Research Interests

Explore related searches

Professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

José Miguel Rivera-Caravaca is a Profesor Permanente Laboral at Universidad de Murcia, Spain. His research focuses on cardiovascular health, particularly atrial fibrillation, anticoagulation therapy, and the assessment of bleeding risks in patients. Recent publications include comparative analyses of bleeding-risk scores and studies on the impacts of lifestyle and multimorbidity on clinical outcomes in atrial fibrillation patients.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (3)

María del Pilar Ramos-Bratos

Universidad de Murcia

SPAIN

View details

Vanessa Roldan

Associated Professor Hematology

Universidad de Murcia Facultad de Medicina

SPAIN

View details

Jose Maria Arribas Leal

Associate professor of cardiovascular surgery

Universidad de Murcia Facultad de Medicina

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

José Miguel Rivera-Caravaca

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Association between baseline adherence to a healthy lifestyle with ischemic and major cardiovascular events in patients with atrial fibrillation.

The Neutrophil-to-Lymphocyte Ratio Is an Independent Inflammatory Biomarker for Adverse Events in Patients With Atrial Fibrillation: Insights From the Murcia AF Project II (MAFP-II) Cohort Study

A comparative analysis of HAS-BLED, ORBIT, DOAC, and AF-BLEED bleeding-risk scores in anticoagulated patients with atrial fibrillation: a report from the prospective Murcia atrial fibrillation project III (MAFP-III) cohort

Evaluation of the Presence of Native Valvular Disease in Patients With Atrial Fibrillation Using the EHRA (Evaluated Heartvalves, Rheumatic, or Artificial) Classification

Spanish Center’s Early Experience With Donation Following Circulatory Death in Heart Transplantation

Poor clinical outcomes associated to multimorbidity, frailty and malnutrition in patients with atrial fibrillation.

Advances in the medical treatment and diagnosis of intracranial hemorrhage associated with oral anticoagulation.

Patients with atrial fibrillation and common exclusion criteria from clinical trials are at high risk of clinical events: the Murcia AF Project II (MAFP-II) cohort study.

Impact of prior oral anticoagulation therapies on post‐discharge outcomes after COVID‐19: Results from a global federated health network analysis

Navigating the bleeding risk dilemma in patients with atrial fibrillation on therapy with direct-acting oral anticoagulants: Comparing the HAS-BLED vs. DOAC Score

Collaborators (3)

María del Pilar Ramos-Bratos

Vanessa Roldan

Jose Maria Arribas Leal

Make your next move.